The main study outcome was anemia at baseline and after 1 year. Anemia was defined as Hb < 11 g/dL as the definition in the study of Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)28. We further defined more severe anemia as Hb < 10 g/dL since ESAs therapy was usually started below this level by current clinical practice29. Hemoglobin at 1 year was determined by simple linear regression with all hemoglobin measurements in this 1 year.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.